In this single handbook the editors aim to give a diverse audience of readers a complete account of all aspects of PVC – from monomer manufacture to polymerization; the gamut of such additives as stabilizers, lubricants, plasticizers, impact modifiers, fillers and reinforcing agents; blends and alloys; compounding and processing; characterization; combustion resistance and weatherability; product engineering design; applications; environmental and safety; and finally
ERYtech Pharma has obtained authorization from Afssaps to open a pharmaceutical headquarters in Lyon.
The activity of this new headquarters will include the export of products made by hand in Europe.
The first manufacturing unit is designed in accordance with European Directives and the Food and Drug U.S. (FDA's) allows the production of clinical batches and allow the manufacture of commercial batches on an industrial scale.
Mersana has announced positive results from preclinical studies for its second development candidate, XMT-1107. The studies showed that XMT-1107, a new analogue of fumagillin antiangiogenic conjugated FLEXIM (R) owned by Mersana showed a higher antitumor activity in xenograft tumor models in comparison with other antiangiogenic agents and extended exposure to the drug conjugate, supporting potential clinical utility of XMT-1107 as an anticancer agent.
"We are encouraged by the progress we are seeing today with XMT-1107, which addresses a new mechanism to inhibit proliferation of endothelial cells and has the potential to address a wide variety of angiogenic tumors, dijoJulie Olson, CEO of Mersana. "The first drugs in this class showed a promising activity in clinical practice but was interrupted due to the reversible neurological toxicity. The combination of our new" warhead "from fumagillin to FLEXIM using a specific link technology reduces exposure to the CNS in animal models for detection limits below. We hope moving XMT-1107 in clinical studies in early 2010. "